Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 26:11:601820.
doi: 10.3389/fonc.2021.601820. eCollection 2021.

Boron Neutron Capture Therapy: A Review of Clinical Applications

Timothy D Malouff  1 , Danushka S Seneviratne  1 , Daniel K Ebner  2 , William C Stross  1 , Mark R Waddle  1 , Daniel M Trifiletti  1 , Sunil Krishnan  1
Affiliations
Review

Boron Neutron Capture Therapy: A Review of Clinical Applications

Timothy D Malouff et al. Front Oncol. .

Abstract

Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget's disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.

Keywords: boron neutron capture; boron neutron capture therapy (BNCT); fast neutrons; particles; radiation.

PubMed Disclaimer

Conflict of interest statement

DT has received clinical trial funding from Novocure and publishing fees from Springer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Injected boron compounds are preferentially found in tumor cells, which are then irradiated with thermal neutrons. The boron then undergoes a reaction, giving an alpha particle and an inert lithium ion. The alpha particle then damages the tumor cell with a finite range.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nedunchezhian K, Aswath N, Thiruppathy M, Thirugnanamurthy S. Boron Neutron Capture Therapy - A Literature Review. J Clin Diagn Res (2016) 10(12):Ze01–ze4. 10.7860/jcdr/2016/19890.9024 - DOI - PMC - PubMed
    1. Sauerwein W, Wittig A, Moss R, Nakagawa K. Neutron Capture Therapy: Principles and Applications. London: Springer Heidelberg New York Dordrecht; (2012).
    1. Barth RF, Zhang Z, Liu T. A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun (Lond) (2018) 38(1):36. 10.1186/s40880-018-0280-5 - DOI - PMC - PubMed
    1. Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, et al. . Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery (1999) 44(6):1182–92; discussion 92-3. 10.1097/00006123-199906000-00013 - DOI - PubMed
    1. Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzen L, et al. . Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol (2008) 88(2):183–91. 10.1016/j.radonc.2006.04.015 - DOI - PubMed